Generic drug maker
, said Tuesday that its subsidiary
has received final approval from the Food and Drug Administration for its Pravastatin tablets.
The Woodcliff Lake, N.J.-based Barr said that the tablets are a generic version of
Pravachol tablets used for treatment of coronary conditions. The company plans to launch the product immediately.
Pliva added that it has also received tentative approval for its Pravastatin 80mg tablets and plans to launch the product following the expiration of a competitors 180-day generic drug exclusivity period and subsequent final approval of Pliva's application.
This story was created through a joint venture between TheStreet.com and IRIS.